Neupro (Rotigotine)

Rotigotine, the active ingredient in Neupro, is a dopamine agonist presented as a transdermal patch for transdermal use. It provides continuous dopaminergic stimulation to manage motor symptoms of Parkinson's disease and to alleviate symptoms of restless legs syndrome in adult patients.

GNH USA supplies Neupro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to this specialized therapy for qualified healthcare providers. The company adheres to stringent quality standards and offers comprehensive logistics support to ensure product integrity throughout the supply chain.

Neupro (rotigotine) is a dopamine agonist used to manage disorders associated with dopaminergic deficiency. - Parkinson's disease (monotherapy): Improves motor symptoms and reduces “off” time in patients not adequately controlled by levodopa alone. - Parkinson's disease (adjunct therapy): Used with levodopa to smooth fluctuations and extend the duration of symptom control. - Restless legs syndrome: Decreases the frequency and severity of uncomfortable leg sensations and urges to move in adults with moderate to severe RLS.

Rotigotine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Skin irritation at the patch site: Redness, itching or rash where the patch is applied. - Nausea: Mild to moderate feeling of stomach upset. - Dizziness: Light‑headedness, especially when standing quickly. - Sleep disturbances: Insomnia or vivid dreams. - Fatigue: General tiredness or lack of energy.

Serious or Rare Side Effects: - Hallucinations: Visual or auditory disturbances. - Orthostatic hypotension: Significant drop in blood pressure upon standing. - Impulse control disorders: Compulsive gambling, shopping or hypersexuality. - Severe skin reactions: Bullous dermatitis or necrosis at the application site. - Depression or suicidal thoughts: Worsening mood or emergent suicidal ideation.

When prescribing rotigotine, clinicians should consider several precautionary measures to ensure safe use. - Cardiovascular assessment: Evaluate for history of arrhythmias or heart disease before initiating therapy. - Psychiatric monitoring: Observe for emergence of hallucinations, depression or impulse control changes. - Concomitant dopaminergic drugs: Adjust doses to avoid excessive dopaminergic stimulation. - Renal or hepatic impairment: Use with caution and monitor clinical response in patients with organ dysfunction. - Pregnancy and lactation: Avoid use unless the potential benefit justifies the potential risk, as safety data are limited. - Store at room temperature: Keep patches below 25 °C in the original packaging, protected from moisture and direct sunlight.

Rotigotine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - MAO‑B inhibitors: Combined use may lead to hypertensive crises or severe orthostatic hypotension. - Antipsychotics with strong dopamine blockade (e.g., haloperidol): May markedly reduce rotigotine’s therapeutic effect.

Moderate Interactions (Monitor Closely): - Other dopamine agonists or levodopa: May increase risk of dyskinesia or hallucinations; dose adjustments may be needed. - CYP3A4 inhibitors (e.g., ketoconazole): Can raise rotigotine plasma levels, requiring careful monitoring. - CYP3A4 inducers (e.g., rifampicin): May lower rotigotine concentrations, potentially reducing efficacy. - Antihypertensive agents: Additive blood pressure‑lowering effect may cause symptomatic hypotension.